Trial Profile
An Observational Study of the Real-life Management of Psoriasis Patients Treated With Otezla (Apremilast) in Belgium
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms OTELO
- Sponsors Celgene Corporation
- 03 Jan 2022 Primary endpoint has been met (Proportion of patients with Patient Benefit Index for skin diseases (standard version) (PBI-S) 1 at 6 months after apremilast initiation.)as per Results published in the Advances in Therapy
- 03 Jan 2022 Results assessing effectiveness and safety of apremilast for the treatment of moderate to severe psoriasis published in the Advances in Therapy
- 06 Feb 2020 Status changed from active, no longer recruiting to completed.